SWIBCO

SmartCella Holding AB raises SEK 328 million to advance and accelerate development of the company’s technologies

Mon, Sep 27, 2021 13:23 CET

SmartCella Holding AB, an innovative biotechnology and medtech company, today announces the raising of SEK 328 million to further advance and accelerate the development of core technologies in the company’s three business units, Procella Therapeutics, Smartwise and SvedMed Solutions. The financing, led by advisor SEB, brings together a renowned group of investors with AMF, SEB Pension, Alto Cumulus and Celox joining existing investors including AP4 and the founders Prof. Kenneth Chien, Thomas von Koch and Christian Kinch. For patients who have suffered a heart attack, a large number

Procella Therapeutics and Smartwise enter collaboration with AstraZeneca to develop novel cardiovascular and catheter-based therapies

Mon, May 07, 2018 07:30 CET

The strategic research collaboration and commercialization agreement aims to develop novel stem cell-based therapies for heart failure and novel vascular injection techniques.In patients who have suffered from a heart attack, a large portion of heart cells die, which may cause heart failure and significant mortality and morbidity. The aim of the collaboration with the global biopharmaceutical company AstraZeneca is to develop new ways of regenerating parts of the heart muscle that have been damaged by a heart attack, using Procella Therapeutics’ stem cell technology, as well as novel

Share

SmartCella Holding AB raises SEK 328 million to advance and accelerate development of the company’s technologies

Procella Therapeutics and Smartwise enter collaboration with AstraZeneca to develop novel cardiovascular and catheter-based therapies